Expert Interview
Discussing the new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
Ticker(s): BOEHRINGER INGELHEIMInstitution: Mount Sinai
- Currently transferring to lead the lung cancer program at Mount Sinai in NYC (from University of Colorado)
- Very familiar with the results from the Phase II Study of Poziotinib for EGFR Exon-20 Mutations presented at the 2018 IASLC World Conference on Lung Cancer.
- Current interest is in biomarker developments for early detection, chemoprevention and treatment of lung cancer. He is also studying markers related to molecular targeted therapies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
